Patents Assigned to Novartis Vaccines and Diagnostics, Inc.
  • Substituted benzimidazoles and methods of preparation
    Patent number: 7767820
    Abstract: Methods for preparing new substituted benzimidazole compounds having formula (I) useful for treating kinase mediated disorders are provided wherein R1, R2, R3, R4, a, b, and c are defined herein
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: August 3, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Martin Dimitroff, Bridget R. Miller, Brady S. Stillwell, David A. Siesel, Tyson Swiftney, Brian Diaz, Danlin Gu, Jonathan P. Van Dyck, David Ryckman, Daniel J. Poon, Teresa E. Pick
  • Compositions and methods for treating intracellular diseases
    Patent number: 7763589
    Abstract: The present invention provides methods of treating intracellular infections comprising the step of administering a vector construct which directs the expression of at least one immunogenic portion of an antigen derived from an intracellular pathogen, and also administering to the warm-blooded animal a protein which comprises the immunogenic portion of the antigen, such that an immune response is generated.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: July 27, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Matti Sallberg, David R. Milich, William T. L. Lee
  • Stabilized FGF formulations containing reducing agents
    Patent number: 7754686
    Abstract: Stabilized FGF compositions are provided. The compositions comprise FGF or variant thereof and at least one reducing agent in an amount sufficient to inhibit FGF oxidation. Methods for increasing stability of FGF or variant thereof in a liquid or lyophilized composition and for increasing storage stability of such a composition are also provided.
    Type: Grant
    Filed: August 31, 2001
    Date of Patent: July 13, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa
  • METHODS OF THERAPY FOR B-CELL MALIGNANCIES USING ANTAGONIST ANTI-CD40 ANTIBODIES
    Publication number: 20100172912
    Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.
    Type: Application
    Filed: September 28, 2009
    Publication date: July 8, 2010
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: KETING CHU, LORIANNE K. MASUOKA
  • METHOD FOR TREATING MULTIPLE SCLEROSIS
    Publication number: 20100172869
    Abstract: Methods for treating multiple sclerosis (MS) and clinically isolated syndromes suggestive of MS are provided. The methods comprise administering a therapeutically effective dose of interferon-beta (IFN-beta) to a subject in need thereof, where the dose is administered intramuscularly with a dosing frequency of two- to three-times per week.
    Type: Application
    Filed: December 18, 2009
    Publication date: July 8, 2010
    Applicant: NOVARTIS VACCINES AND DIAGNOSTIC, INC.
    Inventor: Lorianne K. MASUOKA
  • Enhancement of the immune response for vaccine and gene therapy applications
    Patent number: 7744900
    Abstract: Expression cassettes are provided comprising a promoter operably linked to a nucleic acid molecule which, when transcribed in vivo, forms double-stranded RNA that induces the production of interferon. Expression cassettes also are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, forms a ribozyme or antisense RNA molecule that stimulates an immune response. In addition, expression cassettes are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, stimulates apoptosis. Finally, gene delivery vectors are provided which contain such expression cassettes, host cells containing the gene delivery vectors, and methods of utilizing the expression cassettes, gene delivery vectors, and host cells.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: June 29, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Thomas W Dubensky, Jr., John M Polo, Barbara A Belli, Silvia Perri, Timothy C Fong
  • Substituted benzimidazoles and methods of their use
    Patent number: 7732465
    Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: June 8, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
  • Compositions for inducing immune responses
    Patent number: 7731967
    Abstract: The invention provides, inter alia, immunogenic compositions comprising a first antigen, at least two adjuvants, wherein a first adjuvant comprises a polymer derived from poly(lactides) and/or poly(lactide-co-glycolides), and wherein a second adjuvant comprises an imidazoquinoline, wherein said first antigen is encapsulated within, adsorbed or conjugated to, co-lyophilized or mixed with said first adjuvant, and a pharmaceutically acceptable excipient, wherein said composition elicits a cellular immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions, methods for producing a cytotoxic-T lymphocyte (CTL) response in a vertebrate subject, and methods of immunization.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: June 8, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Manmohan Singh
  • Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
    Patent number: 7728010
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: June 1, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Payman Amiri, Wendy Fantl, Teresa Hansen, Barry Haskell Levine, Christopher McBride, Daniel J Poon, Savithri Ramurthy, Paul A Renhowe, Cynthia M Shafer, Sharadha Subramanian, Leonard Sung
  • Human FGF-21 gene and gene expression products
    Patent number: 7723297
    Abstract: This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: May 25, 2010
    Assignees: Kyoto University, Novartis Vaccines and Diagnostics, Inc.
    Inventors: Nobuyuki Itoh, Michael Kavanaugh
  • Expression of HIV polypeptides and production of virus-like particles
    Patent number: 7718401
    Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.
    Type: Grant
    Filed: February 6, 2008
    Date of Patent: May 18, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Susan W. Barnett, Jan zur Megede, Indresh Srivastava, Ying Lian, Karin Hartog, Hong Liu, Catherine Greer, Mark Selby, Christopher Walker
  • Microparticle-based transfection and activation of dendritic cells
    Patent number: 7713739
    Abstract: The present invention provides an effective method for the transfection of dendritic cells by non-viral methods. The present invention provides this benefit by incubating dendritic cells and a specified transfection agent. The transfection agent comprises a polynucleotide and microparticles, with the microparticles being comprised of biodegradable polymer and cationic detergent. The dendritic cells and transfection agent are incubated for a time sufficient to transfect the dendritic cells with the polynucleotide.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: May 11, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: John J. Donnelly, Kimberly S. Denis-Mize, Gary S. Ott
  • Fluorogenic dyes
    Patent number: 7704756
    Abstract: Fluorogenic or chromogenic dyes are useful as reporter molecules for detecting cell entry by a specific molecule.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: April 27, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Daniel J. Suich, Ronald N. Zuckermann
  • Gene products differentially expressed in cancerous cells
    Patent number: 7700359
    Abstract: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: April 20, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Vivien W. Chan, Jaime Escobedo, Pablo Dominguez Garcia, Rhonda Hansen, Joerg Kaufmann, Giulia C. Kennedy, George Lamson, Edward J. Moler, Filippo Randazzo, Christoph Reinhard, Julie Sudduth-Klinger
  • MODIFIED HIV ENV POLYPEPTIDES
    Publication number: 20100092502
    Abstract: Polynucleotide encoding modified HIV Env polypeptides are disclosed. The Env polypeptides are modified so as to expose at least part of the CD4 binding region. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Application
    Filed: November 19, 2009
    Publication date: April 15, 2010
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Susan Barnett, Karin Hartog, Eric Martin
  • Vectors for expression of hml-2 polypeptides
    Publication number: 20100086565
    Abstract: A nucleic acid vector comprising: (i) a promoter; (ii) a sequence encoding a HML-2 polypeptide operably linked to said promoter; and (iii) a selectable marker. Preferred vectors comprise: (I) a eukaryotic promoter; (ii) a sequence encoding a HML-2 polypeptide downstream of and operably linked to said promoter, (iii) a prokaryotic selectable marker; (iv) a prokaryotic origin of replication; and (v) a eukaryotic transcription terminator downstream of and operably linked to said sequence encoding a HML-2 polypeptide. Vectors of the invention are particularly useful for expression of HML-2 polypeptides either in vitro (e.g. for later purification). Or in vivo (e.g. for nucleic acid immunization). They are well suited to nucleic acid immunization against prostrate tumors. A preferred HML-2 is PCAV, which is located in chromosome 22 at 20.428 megabases (22q11.2).
    Type: Application
    Filed: June 13, 2003
    Publication date: April 8, 2010
    Applicant: Novartis vaccines and diagnostics Inc
    Inventors: Stephen F. Hardy, John Donnelly, Jan zur Megede
  • 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
    Patent number: 7691866
    Abstract: New substituted quinazoline, quinoxaline, quinoline and isoquinoline compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: April 6, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Savithri Ramurthy, Paul A. Renhowe, Sharadha Subramanian
  • Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
    Patent number: 7674769
    Abstract: Methods for prophylactically or therapeutically treating severe pneumonia involve administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog, preferably at low doses to avoid adverse side effects.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: March 9, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Abla Creasey
  • METHOD FOR THE PURIFICATION OF ALPHAVIRUS REPLICON PARTICLES
    Publication number: 20100055128
    Abstract: Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. in one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided. Also disclosed are methods of characterizing alphavirus replicon particles and utilizing these materials for vaccines and gene-based therapeutics.
    Type: Application
    Filed: September 18, 2008
    Publication date: March 4, 2010
    Applicant: Novartis Vaccines and Diagnostics Inc
    Inventors: John M. Polo, Catherine Greer, Maria Calderon-Cacia, Daniel De La Vega, JR., Thomas W. Dubensky, JR.
  • Human immunodeficiency virus (HIV) nucleotide sequences
    Patent number: RE41158
    Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: March 2, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Paul Luciw, Dino Dina
  • Self-cooling joint connection for abutting segments in a gas turbine engine
    Patent number: 5167485
    Abstract: A joint connection for abutting, circumferentially extending segments in a gas turbine engine, such as turbine nozzle segments, includes a sealing member which is insertable between longitudinally extending slots formed in the abutting side edges of two adjacent segments. The segments are each formed with a number of grooves which are longitudinally spaced along the length of the slots therein, and which extend beneath the sealing member carried within the slots. A cooling air flow path is thus formed extending from one side of the sealing member, into the longitudinal slot of each segment and then through the grooves to the opposite side of the sealing member so that the entire joint connection or seal region between the abutting side edges of the segments is cooled.
    Type: Grant
    Filed: April 6, 1992
    Date of Patent: December 1, 1992
    Assignee: General Electric Company
    Inventor: John H. Starkweather